NEVVI Medicare utilization intelligence

← back

SEETHARAM, MAHESHMD, FACP NPI 1487781175 Clinician

Hematology-Oncology · PHOENIX, AZ

Specialty Hematology-Oncology — from billed Medicare claims
In practice about 28 years since medical school (class of 1998, self-reported to CMS)
Location PHOENIX, AZ · NPPES registered location
Active in data Billed Medicare 2020–2024 (5 consecutive years)
Scale 65 codes billed · 107,946 disclosed services (CY2024 — most recent year in data)
Current groups
member of 2 groups; the volumes below are this clinician's personal volume and are not attributed to any single group

Group affiliation since 2019

20192026
DHEW IND HLTH SV HLTH SVS AND MNTL HLTH ADM
2019–2026
MAYO CLINIC ARIZONA
2019–2026

The roster archive begins in 2019, so a span starting at 2019 may reach back further. Membership spans only — no volume is attributed to any group here.

NPPES registry · CMS Doctors & Clinicians registry · Medicare Part B physician/supplier claims · NPPES record last updated 2020-09

Year: 2024 · 2023 · 2022  · 2021  · 2020 

Provider overview · all codes · CY2024

The full analytics for this provider

Premium

The billed-volume positioning, practice focus, and economics behind this provider — computed on the same disclosed Medicare Part B data.

This provider's disclosed Medicare payments across all codes were in CY2024. Included with Platform.

  • Payment, service & beneficiary totals — the disclosed scale, all codes
  • Practice profile — focus & reach — top codes by share of services
  • Office vs. facility setting mix — place-of-service code split
  • Volume over five years — discrete yearly counts, no rate
  • Peer positioning — service volume — percentile among specialty peers, cohort & year disclosed
  • Peer positioning — code breadth — how many codes billed, vs peers

Peer positioning shows billed-volume and code-breadth positions among specialty peers, not measures of care (a provider's true volume position can only be higher, never lower). All figures disclosed Medicare Part B fee-for-service; volumes are personal to this NPI, not attributed to any group.

Notify me at launch → Or see a live example profile →

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J9271 Injection, pembrolizumab, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J1453 Injection, fosaprepitant, 1 mg
J9267 Injection, paclitaxel, 1 mg
J9177 Injection, enfortumab vedotin-ejfv, 0.25 mg
J9299 Injection, nivolumab, 1 mg
J9025 Injection, azacitidine, 1 mg
Q5110 Injection, filgrastim-aafi, biosimilar, (nivestym), 1 microgram
J9263 Injection, oxaliplatin, 0.5 mg
J9264 Injection, paclitaxel protein-bound particles, 1 mg
J0897 Injection, denosumab, 1 mg
J9173 Injection, durvalumab, 10 mg
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
J9047 Injection, carfilzomib, 1 mg
J9305 Injection, pemetrexed, not otherwise specified, 10 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J9041 Injection, bortezomib, 0.1 mg
J2469 Injection, palonosetron hcl, 25 mcg
Q5119 Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg
Q5115 Injection, rituximab-abbs, biosimilar, (truxima), 10 mg
J2405 Injection, ondansetron hydrochloride, per 1 mg
J0894 Injection, decitabine, 1 mg
Q5118 Injection, bevacizumab-bvzr, biosimilar, (zirabev), 10 mg
J0461 Injection, atropine sulfate, 0.01 mg
96375 Injection of additional new drug or substance into vein
96413 Administration of chemotherapy into vein, 1 hour or less
J9395 Injection, fulvestrant, 25 mg
J9045 Injection, carboplatin, 50 mg
Q5108 Injection, pegfilgrastim-jmdb (fulphila), biosimilar, 0.5 mg
J9201 Injection, gemcitabine hydrochloride, not otherwise specified, 200 mg
J9206 Injection, irinotecan, 20 mg
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96415 Administration of chemotherapy into vein, each additional hour
96372 Injection of drug or substance under skin or into muscle
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J9217 Leuprolide acetate (for depot suspension), 7.5 mg
96417 Administration of additional new drug or substance into vein, 1 hour or less
36591 Collection of blood sample from implanted device
J9190 Injection, fluorouracil, 500 mg
J1200 Injection, diphenhydramine hcl, up to 50 mg
96361 Infusion into a vein for hydration, each additional hour
J7030 Infusion, normal saline solution , 1000 cc
J3490 Unclassified drugs
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
J3475 Injection, magnesium sulfate, per 500 mg
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
99203 New patient office or other outpatient visit with low level of medical decision making, if using time, 30 minutes or more
J3489 Injection, zoledronic acid, 1 mg
96411 Administration of additional new drug or substance into vein using push technique
99212 Established patient office or other outpatient visit with straightforward medical decision making, if using time, 10 minutes or more
99215 Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
99204 New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more
96360 Infusion into a vein for hydration, 31-60 minutes
G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's
96374 Injection of drug or substance into vein
J7040 Infusion, normal saline solution, sterile (500 ml = 1 unit)
96409 Administration of chemotherapy into vein using push technique
96523 Irrigation of implanted venous access drug delivery device
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
99211 Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.